The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial
Open accessAbstract
Background: Long acting insulin detemir administered intranasally for three weeks enhanced memory for adults with Alzheimer’s disease dementia (AD) or amnestic mild cognitive impairment (MCI). The investigation of longer-term administration is necessary to determine whether benefits persist, whether they are similar to benefits provided by regular insulin, and whether either form of insulin therapy affects AD biomarkers. Objective: The present study aimed to determine whether four months of treatment with intranasal insulin detemir or regular insulin improves cognition, daily functioning, and AD biomarkers for adults with MCI or AD. Methods: This randomized, double-blind, placebo-controlled trial included an intent-to-treat sample consisting of 36 adults diagnosed with MCI or mild to moderate AD. Participants received placebo ( n = 12), 40 IU of insulin detemir ( n = 12), or 40 IU of regular insulin ( n = 12) daily for four months, administered with a nasal delivery device. A cognitive battery was administered at baseline and after two and four months of treatment. MRI was administered for all participants and lumbar puncture for a subset ( n = 20) at baseline and four months. The primary outcome was change from baseline to four months on a memory composite (sum of Z scores for delayed list and story recall). Secondary outcomes included: global cognition (Alzheimer’s Disease Assessment Scale-Cognition), daily functioning (Dementia Severity Rating Scale), MRI volume changes in AD-related regions of interest, and cerebrospinal fluid AD markers. Results: The regular insulin treated group had better memory after two and four months compared with placebo ( p < 0.03). No significant effects were observed for the detemir-assigned group compared with the placebo group, or for daily functioning for either group. Regular insulin treatment was associated with preserved volume on MRI. Regular insulin treatment was also associated with reduction in the tau-P181/Aβ 42 ratio. Conclusion: Future research is warranted to examine the mechanistic basis of treatment differences, and to further assess the efficacy and safety of intranasal insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A device for IN delivery that had been successfully used in previous studies 75,76,107 proved unreliable in the first 49 participants because of malfunctions of a newly added electronic timer.”
From Intranasal insulin (2021) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Self-citationIntranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Self-citationRoberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Petersen, R. C., & Rocca, W. A. (2008) · Neuroepidemiology · doi:10.1159/000115751 · Cited by 797
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · cited 1×
“phorylation in preclinical models [4].”
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Self-citationBrain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Self-citationNagpal, R., Neth, B. J., Wang, S., Craft, S., & Yadav, H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.032 · Cited by 653
Self-citationIntranasal drug delivery: opportunities and toxicologic challenges during drug development
Keller, L.-A., Merkel, O. M., & Popp, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00891-5 · Cited by 636
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Self-citationPathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Tryphena, K. P., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 438
Insulin and Insulin Resistance in Alzheimer’s Disease
Sędzikowska, A., & Szablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189987 · Cited by 414
Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives
Béard, E., Lengacher, S., Dias, S., Magistretti, P. J., & Finsterwald, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.825816 · Cited by 326
Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline
Spinelli, M., Fusco, S., & Grassi, C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00788 · Cited by 290
The brain as an insulin-sensitive metabolic organ
Milstein, J. L., & Ferris, H. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101234 · Cited by 274
Tumminia, A., Vinciguerra, F., Parisi, M., & Frittitta, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113306 · Cited by 263
Wang, Z., Xiong, G., Tsang, W. C., Schätzlein, A. G., & Uchegbu, I. F. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258152 · Cited by 247
Анатольевич, П. И., Costa-Nunes, J. P., Kasatkin, V. N., Veniaminova, E. A., Demchenko, A. G., Lyundup, A. V., Lesch, K., Ponomarev, E. D., & Strekalova, T. V. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12866 · Cited by 215
Nagpal, R., Neth, B. J., Wang, S., Mishra, S. P., Craft, S., & Yadav, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102950 · Cited by 197
Self-citationMultifactorial Hypothesis and Multi-Targets for Alzheimer’s Disease
Gong, C., Liu, F., & Iqbal, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179921 · Cited by 188
Chornenkyy, Y., Wang, W., Wei, A. L., & Nelson, P. T. (2018) · Brain Pathology · doi:10.1111/bpa.12655 · Cited by 189
Dietary habits, lifestyle factors and neurodegenerative diseases
Popa‐Wagner, A., Dumbrava, D., Dumitrascu, D., Căpitănescu, B., Petcu, E. B., Surugiu, R., & Fang, W.-H. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.266045 · Cited by 190
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
Intranasal Insulin for Alzheimer’s Disease
Hallschmid, M. (2021) · CNS Drugs · doi:10.1007/s40263-020-00781-x · Cited by 188
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H., & Lin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 190
Insulin action in the brain: cell types, circuits, and diseases
Chen, W., Cai, W., Hoover, B., & Kahn, C. R. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.03.001 · Cited by 184
Is Alzheimer’s Disease Risk Modifiable?
Serrano‐Pozo, A., & Growdon, J. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad181028 · Cited by 169
Current and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo-Mínguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 142
Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review
Avgerinos, K. I., Kalaitzidis, G., Malli, A., Kalaitzoglou, D., Myserlis, E. P., & Lioutas, V. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8768-0 · Cited by 140
Brain Metabolic Alterations in Alzheimer’s Disease
Ardanaz, C. G., Ramírez, M. J., & Solas, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073785 · Cited by 135
Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel‐Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 131
Amyloid-beta and tau protein beyond Alzheimer’s disease
Abyadeh, M., Gupta, V., Paulo, J. A., Mahmoudabad, A. G., Shadfar, S., Mirshahvaladi, S., Gupta, V. B., Nguyen, C. T. O., Finkelstein, D. I., You, Y., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.386406 · Cited by 126
Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease
Hölscher, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00088 · Cited by 122
Nose-to-brain drug delivery: from bench to bedside
Drath, I., Richter, F., & Feja, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00481-w · Cited by 132
Cerebrovascular insulin receptors are defective in Alzheimer’s disease
Leclerc, M., Bourassa, P., Tremblay, C., Caron, V., Sugère, C., Émond, V., Bennett, D. A., & Calon, F. (2022) · Brain · doi:10.1093/brain/awac309 · Cited by 113
Safety of intranasal human insulin: A review
Schmid, V., Kullmann, S., Gfrörer, W., Hund, V., Hallschmid, M., Lipp, H., Häring, H., Preissl, H., Fritsche, A., & Heni, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13279 · Cited by 110
Hallschmid, M. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12934 · Cited by 113
Vinuesa, Á., Pomilio, C. J., Gregosa, A., Bentivegna, M., Presa, J., Bellotto, M., Saravia, F., & Beauquis, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653651 · Cited by 117
Gonçalves, R. A., Wijesekara, N., Fraser, P. E., & Felice, F. G. D. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00017 · Cited by 108
Intranasal insulin in Alzheimer's disease: Food for thought
Chapman, C. D., Schiöth, H. B., Grillo, C. A., & Benedict, C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.037 · Cited by 111
Dierssen, M., Fructuoso, M., de Lagrán, M. M., Marzia Perluigi, A., & Barone, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00670 · Cited by 106
Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function
Arvanitakis, Z., Wang, H.-Y., Capuano, A. W., Khan, A., Taïb, B., Anokye‐Danso, F., Schneider, J. A., Bennett, D. A., Ahima, R. S., & Arnold, S. E. (2020) · Annals of Neurology · doi:10.1002/ana.25826 · Cited by 102
Alzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98
Benedict, C., & Grillo, C. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00215 · Cited by 101
Non-Invasive Strategies for Nose-to-Brain Drug Delivery.
Ja, T., Quispe, R. C., Khan, F. A., & Новак (2020) · PubMed · Cited by 114
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 97
Alzheimer’s disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links
Rojas, M., Chávez-Castillo, M., Bautista, J., Ortega, Á., Nava, M., Salazar, J. J., Díaz-Camargo, E. A., Medina, O., Rojas, J., & Bermúdez, V. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i6.745 · Cited by 98
Sun, Y., Wang, Y., Chen, S., Chen, Y., Shen, J., Yao, W., Gao, X., & Chen, S. (2020) · Theranostics · doi:10.7150/thno.44370 · Cited by 95
Hayden, M. R. (2019) · Brain Sciences · doi:10.3390/brainsci9100262 · Cited by 95
Metabolic Plasticity of Astrocytes and Aging of the Brain
Morita, M., Ikeshima‐Kataoka, H., Kreft, M., Vardjan, N., Zorec, R., & Noda, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040941 · Cited by 88
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics
Lepiarz-Raba, I., Gbadamosi, I., Florea, R., Paolicelli, R. C., & Jawaid, A. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00382-w · Cited by 90
Quipildor, G. F., Mao, K., Hu, Z., Novaj, A., Cui, M., Gulinello, M. E., Branch, C. A., Gubbi, S., Patel, K., Moellering, D. R., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00065-3 · Cited by 85
Matsuda, S., Nakagawa, Y., Tsuji, A., Kitagishi, Y., Nakanishi, A., & Murai, T. (2018) · Diseases · doi:10.3390/diseases6020028 · Cited by 86
Functions of amyloid precursor protein in metabolic diseases
Guo, Y., Wang, Q., Chen, S., & Xu, C. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154454 · Cited by 89
Multi-target drugs for Alzheimer's disease
Turgutalp, B., & Kızıl, Ç. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.05.005 · Cited by 87
Fatty Acids, Antioxidants and Physical Activity in Brain Aging
Freitas, H. R., Ferreira, G. C., Trevenzoli, I. H., Oliveira, K. J., & Reis, R. A. D. M. (2017) · Nutrients · doi:10.3390/nu9111263 · Cited by 85
McMillan, J. M., Mele, B. S., Hogan, D. B., & Leung, A. A. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000563 · Cited by 80
Imaging of intranasal drug delivery to the brain.
Veronesi, M. C., Alhamami, M., Miedema, S. B., Yun, Y., Ruiz-Cardozo, M. A., & Vannier, M. W. (2020) · PubMed · Cited by 88
The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases
Qiu, Y., Huang, S., Peng, L., Yang, L., Zhang, G., Liu, T., Yan, F., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70213 · Cited by 90
Insulin transport into the brain
Gray, S. M., & Barrett, E. J. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00240.2017 · Cited by 80
Obesity and Alzheimer’s disease: Molecular bases
Picone, P., Carlo, M. D., & Nuzzo, D. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14758 · Cited by 77
Diabetes and Alzheimer’s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?
Potenza, M. A., Sgarra, L., Desantis, V., Nacci, C., & Montagnani, M. (2021) · Antioxidants · doi:10.3390/antiox10081257 · Cited by 78
Gray, S. C., Kinghorn, K. J., & Woodling, N. S. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.272571 · Cited by 76
Role of Insulin in Neurotrauma and Neurodegeneration: A Review
Shaughness, M., Acs, D., Brabazon, F., Hockenbury, N., & Byrnes, K. R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.547175 · Cited by 78
Teo, E., Ravi, S., Barardo, D., Kim, H.-S., Fong, S., Cazenave-Gassiot, A., Tan, T. Y., Ching, J., Kovalik, J.-P., Wenk, M. R., et al. (2019) · eLife · doi:10.7554/elife.50069 · Cited by 72
State of the science on brain insulin resistance and cognitive decline due to Alzheimer's disease
Rhea, E. M., Leclerc, M., Yassine, H. N., Capuano, A. W., Tong, H., Petyuk, V. A., Macauley, S. L., Fioramonti, X., Carmichael, O., Calon, F., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0814 · Cited by 70
Antidiabetic Drugs in the Treatment of Alzheimer’s Disease
Michailidis, M., Tata, D. Α., Μoraitou, D., Kavvadas, D., Karachrysafi, S., Papamitsou, T., Vareltzis, P. K., & Papaliagkas, V. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094641 · Cited by 71
Kim, B., Elzinga, S. E., Henn, R. E., McGinley, L. M., & Feldman, E. L. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104541 · Cited by 71
Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases
Yeo, X. Y., Cunliffe, G., Ho, R., Lee, S. S., & Jung, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020343 · Cited by 66
Insulin resistance, cognition, and Alzheimer disease
Kim, A. B., & Arvanitakis, Z. (2023) · Obesity · doi:10.1002/oby.23761 · Cited by 68
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
The Implication of the Brain Insulin Receptor in Late Onset Alzheimer’s Disease Dementia
Folch, J., Ettcheto, M., Busquets, O., Sánchez‐López, E., Castro-Torres, R. D., Verdaguer, E., Manzine, P. R., Poor, S. R., García, M. L., Olloquequi, J., et al. (2018) · Pharmaceuticals · doi:10.3390/ph11010011 · Cited by 65
Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease
Kosyakovsky, J., Fine, J. M., Frey, W. H., & Hanson, L. R. (2021) · Pharmaceuticals · doi:10.3390/ph14020095 · Cited by 67
Akel, H., Csóka, I., Ambrus, R., Bocsik, A., Gróf, I., Mészáros, M., Szecskó, A., Kozma, G., Veszelka, S., Deli, M. A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413258 · Cited by 64
Tashima, T. (2020) · Molecules · doi:10.3390/molecules25215188 · Cited by 61
Diabetes: a tipping point in neurodegenerative diseases
Santiago, J. A., Karthikeyan, M., Lackey, M., Villavicencio, D., & Potashkin, J. A. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.09.005 · Cited by 65
Insulin mediated novel therapies for the treatment of Alzheimer's disease
Dubey, S. K., Lakshmi, K. K., Krishna, K. V., Agrawal, M., Singhvi, G., Saha, R. N., Saraf, S., Saraf, S., Shukla, R., & Alexander, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117540 · Cited by 62
Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach
Sabari, S. S., Balasubramani, K., Iyer, M., Babu, H. W. S., Venkatesan, D., Gopalakrishnan, A. V., Narayanaswamy, A., Kumar, N. S., & Vellingiri, B. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03359-y · Cited by 64
Ferreira, S. T. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12959 · Cited by 59
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.010 · Cited by 58
Wong, C. Y. J., Baldelli, A., Hoyos, C. M., Tietz, O., Ong, H. X., & Traini, D. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01558-1 · Cited by 64
Esmaeili, M. H., Enayati, M., Khabbaz, F., Ebrahimian, F., & Salari, A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112359 · Cited by 61
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051399 · Cited by 59
Antidiabetic Drugs in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review
Muñoz-Jiménez, M., Zaarkti, A., García-Arnés, J. A., & García‐Casares, N. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000510677 · Cited by 55
Diabetes and cognitive decline
Bellia, C., Lombardo, M., Meloni, M., Della‐Morte, D., Bellia, A., & Lauro, D. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.07.006 · Cited by 59
Shpakov, A. O., Zorina, I. I., & Derkach, K. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043278 · Cited by 59
Carranza-Naval, M. J., del Marco, À., Hierro‐Bujalance, C., Alves-Martínez, P., Infante‐Garcia, C., Vargas-Soria, M., Herrera, M., Barba-Cordoba, B., Atienza‐Navarro, I., Lubián‐López, S. P., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.741923 · Cited by 56
The “great” controlling nucleotide coenzymes
Veech, R. L., King, M. T., Pawlosky, R. J., Kashiwaya, Y., Bradshaw, P. C., & Curtis, W. (2019) · IUBMB Life · doi:10.1002/iub.1997 · Cited by 53
Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease
Mejido, D. C. P., Peny, J. A., Vieira, M. N. N., Ferreira, S. T., & Felice, F. G. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108115 · Cited by 52
Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies
Goel, H., Kalra, V., Verma, S. K., Dubey, S. K., & Tiwary, A. K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.009 · Cited by 56
Brain insulin resistance and cognitive function: influence of exercise
Malin, S. K., Stewart, N. R., Ude, A. A., & Alderman, B. L. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00375.2022 · Cited by 53
Suarez, A. N., Noble, E. E., & Kanoski, S. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00101 · Cited by 55
Fine, J. M., STROEBEL, B. M., Faltesek, K. A., Terai, K., Haase, L. R., Knutzen, K. E., Kosyakovsky, J., Bowe, T. J., Fuller, A. K., Frey, W. H., et al. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134567 · Cited by 52
Circulating IGFBP‐2: a novel biomarker for incident dementia
McGrath, E. R., Himali, J. J., Levy, D., Conner, S. C., DeCarli, C. S., Pase, M. P., Courchesne, P., Satizabal, C. L., Vasan, R. S., Beiser, A. S., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50854 · Cited by 49
Meng, L., Li, X., Shen, L., & Ji, H. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.002 · Cited by 49
Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
Cummings, J. L., Ortiz, A. A., Castellino, J., & Kinney, J. W. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15619 · Cited by 54
Duarte, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.044 · Cited by 49
Bose, M., Quipildor, G. F., Ehrlich, M. E., & Salton, S. R. (2022) · Cells · doi:10.3390/cells11223629 · Cited by 47
Johnson, R. J., Tolan, D. R., Bredesen, D. E., Nagel, M. A., Sánchez‐Lozada, L. G., Fini, M. A., Burtis, S., Lanaspa, M. A., & Perlmutter, D. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.01.002 · Cited by 49
The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and “Nose-to-Brain”
Shrewsbury, S. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061720 · Cited by 48
Chung, J. Y., Kim, O. Y., & Song, J. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuab118 · Cited by 47
Metadata
- Authors
- Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., Jung, Y., Maldjian, J., Whitlow, C., & Friedman, S.
- Affiliations
- Wake Forest University Health Sciences (US)
- Alkermes (United States) (US)
- University of Washington (US)
- Stanford Medicine (US)
- The University of Texas Southwestern Medical Center (US)
- Seattle Children's Hospital (US)
- Corresponding author
- Craft, Suzanne
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-03-29
- Volume
- 57
- Issue
- 4
- Pages
- 1325-1334
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5409050
- OpenAlex
- W2600568015
- Cited by
- 335
- References
- 33
- Citations by year
- 2026: 13 · 2025: 40 · 2024: 25 · 2023: 47 · 2022: 32 · 2021: 46 · 2020: 49 · 2019: 46 · 2018: 29 · 2017: 8
- FWCI
- 26.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Alzheimer's Association (ZEN-10-173646)
- National Institute on Aging (P30AG049638)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- intranasal insulin, insulin detemir
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Brain, Cognition, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Organ Size, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Outcome, Nootropic Agents, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
